""""""""Blockade ofCD40L to treat autoimmune diabetes (T1D) -a detailed mechanistic evaluation using RIP-LCMV mice"""""""". Systemic Treatment with antibody to CD40Ligand (aCD40L) can prevent autoimmunity and transplant rejection in several animals models and is currently under evaluation in clinical trials. It is known that aCD40L administration can inhibit expansion and effector functions of aggressive T lymphocytes, but additional regulatory mechanisms have been suggested based on transfer experiments, which would explain the exquisite long-term efficacy of this intervention in many experimental systems. Our preliminary observations demonstrate that CD40L blockade during activation of the autoaggressive response results in generation of ?regulatory? CD II c+/DX5+ APCs that can protect pre-diabetic recipients from disease in an autoantigen specific way. We used the well-established RIP-LCMV transgenic mouse model for virally induced autoimmune diabetes, where a viral antigen is expressed as a ?marker? self-antigen specifically in pancreatic b-cells and is target of the autoimmune response induced by infection with the same virus. Protection by such ?regulatory? APCs was mediated through selective, systemic reduction of autoaggressive CD4 and CD8 cells, but not by generalized immunosuppression. Based on these findings the present application has three long-term goals: 1. Precise characterization and phenotypic analysis of CD 11c+ regulatory APCs. 2. In vivo and in vitro effector mechanisms to achieve antigen specific tolerance (dampening of the autoaggressive response) by CD11c+ conditioned (regulatory) APCs. 3. In vitro generation of regulatory APCs and assessment of their in vivo efficacy. Ultimately, induction of ?regulatory? CD11c+ cells by blocking CD40L during immune activation might constitute a novel and efficacious pathway to achieve long-term antigen-specific tolerance.

Agency
National Institute of Health (NIH)
Institute
National Institute of Allergy and Infectious Diseases (NIAID)
Type
Research Program--Cooperative Agreements (U19)
Project #
1U19AI051973-01
Application #
6543973
Study Section
Special Emphasis Panel (ZAI1)
Project Start
2001-09-30
Project End
2006-08-30
Budget Start
Budget End
Support Year
1
Fiscal Year
2001
Total Cost
Indirect Cost
Name
La Jolla Institute
Department
Type
DUNS #
603880287
City
La Jolla
State
CA
Country
United States
Zip Code
92037
Solomon, Michelle; Balasa, Balaji; Sarvetnick, Nora (2010) CCR2 and CCR5 chemokine receptors differentially influence the development of autoimmune diabetes in the NOD mouse. Autoimmunity 43:156-63
Bresson, Damien; Fradkin, Matthew; Manenkova, Yulia et al. (2010) Genetic-induced variations in the GAD65 T-cell repertoire governs efficacy of anti-CD3/GAD65 combination therapy in new-onset type 1 diabetes. Mol Ther 18:307-16
Bresson, Damien; von Herrath, Matthias (2008) Resuscitating adaptive Tregs with combination therapies? Novartis Found Symp 292:50-60;discussion 60-7, 122-9, 2
Filippi, Christophe M; Juedes, Amy E; Oldham, Janine E et al. (2008) Transforming growth factor-beta suppresses the activation of CD8+ T-cells when naive but promotes their survival and function once antigen experienced: a two-faced impact on autoimmunity. Diabetes 57:2684-92
Yadav, Deepak; Fine, Cody; Azuma, Miyuki et al. (2007) B7-1 mediated costimulation regulates pancreatic autoimmunity. Mol Immunol 44:2616-24
Bresson, D; von Herrath, M (2007) Moving towards efficient therapies in type 1 diabetes: to combine or not to combine? Autoimmun Rev 6:315-22
Martinic, Marianne M; Juedes, Amy E; Bresson, Damien et al. (2007) Minimal impact of a de novo-expressed beta-cell autoantigen on spontaneous diabetes development in NOD mice. Diabetes 56:1059-68
Yadav, Deepak; Sarvetnick, Nora (2007) Immunomodulation of the anti-islet CD8 T cell response by B7-2. J Clin Immunol 27:221-6
Fousteri, Georgia; von Herrath, Matthias; Bresson, Damien (2007) Mucosal exposure to antigen: cause or cure of type 1 diabetes? Curr Diab Rep 7:91-8
Burrer, Renaud; Buchmeier, Michael J; Wolfe, Tom et al. (2007) Exacerbated pathology of viral encephalitis in mice with central nervous system-specific autoantibodies. Am J Pathol 170:557-66

Showing the most recent 10 out of 40 publications